Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Evaluation of potential surrogate endpoints for prediction of overall survival in patients with castration-resistant prostate cancer: trial-level meta-analysis.

Chen W, Li L, Ji S, Song X, Lu W, Zhou T.

Eur J Clin Pharmacol. 2019 Aug 28. doi: 10.1007/s00228-019-02736-8. [Epub ahead of print]

PMID:
31463577
2.

Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review.

Savina M, Gourgou S, Italiano A, Dinart D, Rondeau V, Penel N, Mathoulin-Pelissier S, Bellera C.

Crit Rev Oncol Hematol. 2018 Mar;123:21-41. doi: 10.1016/j.critrevonc.2017.11.014. Epub 2017 Nov 23. Review.

PMID:
29482777
3.

Assessment of Correlation Between Early and Late Efficacy Endpoints to Identify Potential Surrogacy Relationships in Non-Hodgkin Lymphoma: a Literature-Based Meta-analysis of 108 Phase II and Phase III Studies.

Zhu R, Lu D, Chu YW, Chai A, Green M, Zhang N, Jin JY.

AAPS J. 2017 May;19(3):669-681. doi: 10.1208/s12248-017-0056-x. Epub 2017 Feb 21. Review.

PMID:
28224402
4.

Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.

Foster NR, Qi Y, Shi Q, Krook JE, Kugler JW, Jett JR, Molina JR, Schild SE, Adjei AA, Mandrekar SJ.

Cancer. 2011 Mar 15;117(6):1262-71. doi: 10.1002/cncr.25526. Epub 2010 Oct 19.

5.

Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis.

Li H, Wang Z, Tang K, Zhou H, Liu H, Yan L, Guan W, Chen K, Xu H, Ye Z.

Eur Urol Focus. 2018 Jul;4(4):529-539. doi: 10.1016/j.euf.2017.01.004. Epub 2017 Jan 23.

PMID:
28753843
6.

Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.

Wang X, Wang X, Hodgson L, George SL, Sargent DJ, Foster NR, Ganti AK, Stinchcombe TE, Crawford J, Kratzke R, Adjei AA, Kindler HL, Vokes EE, Pang H.

Oncologist. 2017 Feb;22(2):189-198. doi: 10.1634/theoncologist.2016-0121. Epub 2017 Feb 10.

7.

Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA).

Mehra N, Dolling D, Sumanasuriya S, Christova R, Pope L, Carreira S, Seed G, Yuan W, Goodall J, Hall E, Flohr P, Boysen G, Bianchini D, Sartor O, Eisenberger MA, Fizazi K, Oudard S, Chadjaa M, Macé S, de Bono JS.

Eur Urol. 2018 Sep;74(3):283-291. doi: 10.1016/j.eururo.2018.02.013. Epub 2018 Feb 28.

8.

Surrogacy of progression-free survival (PFS) for overall survival (OS) in esophageal cancer trials with preoperative therapy: Literature-based meta-analysis.

Kataoka K, Nakamura K, Mizusawa J, Kato K, Eba J, Katayama H, Shibata T, Fukuda H.

Eur J Surg Oncol. 2017 Oct;43(10):1956-1961. doi: 10.1016/j.ejso.2017.06.017. Epub 2017 Jul 15. Review.

PMID:
28747249
9.
10.

Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer.

Sonpavde G, Pond GR, Armstrong AJ, Galsky MD, Leopold L, Wood BA, Wang SL, Paolini J, Chen I, Chow-Maneval E, Mooney DJ, Lechuga M, Smith MR, Michaelson MD.

BJU Int. 2014 Dec;114(6b):E25-E31. doi: 10.1111/bju.12589. Epub 2014 Jul 17.

11.

The value of surrogate endpoints for predicting real-world survival across five cancer types.

Shafrin J, Brookmeyer R, Peneva D, Park J, Zhang J, Figlin RA, Lakdawalla DN.

Curr Med Res Opin. 2016;32(4):731-9. doi: 10.1185/03007995.2016.1140027. Epub 2016 Jan 25.

PMID:
26743800
12.

Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials.

Petrelli F, Coinu A, Cabiddu M, Borgonovo K, Ghilardi M, Lonati V, Barni S.

Medicine (Baltimore). 2016 Jun;95(26):e3997. doi: 10.1097/MD.0000000000003997. Review.

14.

Surrogate end points for overall survival in breast cancer trials: A review.

Fiteni F, Bonnetain F.

Breast. 2016 Oct;29:44-8. doi: 10.1016/j.breast.2016.06.005. Epub 2016 Jul 9. Review.

15.

Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology.

Sherrill B, Kaye JA, Sandin R, Cappelleri JC, Chen C.

Onco Targets Ther. 2012;5:287-96. doi: 10.2147/OTT.S36683. Epub 2012 Oct 23.

16.

Endpoint surrogacy in oncological randomized controlled trials with immunotherapies: a systematic review of trial-level and arm-level meta-analyses.

Zhang J, Liang W, Liang H, Wang X, He J.

Ann Transl Med. 2019 Jun;7(11):244. doi: 10.21037/atm.2019.04.72. Review.

17.

Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer.

Pilon D, Queener M, Lefebvre P, Ellis LA.

J Med Econ. 2016 Aug;19(8):777-84. doi: 10.3111/13696998.2016.1173042. Epub 2016 Apr 20.

PMID:
27031255
18.

Progression-free survival as a surrogate endpoint for median overall survival in metastatic colorectal cancer: literature-based analysis from 50 randomized first-line trials.

Giessen C, Laubender RP, Ankerst DP, Stintzing S, Modest DP, Mansmann U, Heinemann V.

Clin Cancer Res. 2013 Jan 1;19(1):225-35. doi: 10.1158/1078-0432.CCR-12-1515. Epub 2012 Nov 13.

19.

Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial.

Ray ME, Bae K, Hussain MH, Hanks GE, Shipley WU, Sandler HM.

J Natl Cancer Inst. 2009 Feb 18;101(4):228-36. doi: 10.1093/jnci/djn489. Epub 2009 Feb 10.

20.

Surrogate endpoints for overall survival in lung cancer trials: a review.

Fiteni F, Westeel V, Bonnetain F.

Expert Rev Anticancer Ther. 2017 May;17(5):447-454. doi: 10.1080/14737140.2017.1316196. Epub 2017 Apr 12. Review.

PMID:
28399678

Supplemental Content

Support Center